BioPlan Associates presents research and projections on the pharma sterile fill-finish industry’s future over the next 10 ...

In the evolving landscape of pharmaceutical production, fill-finish contract manufacturing has become a crucial area of focus ...

Regeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and commercialise drugs targeting eye, central nervous system (CNS ...

Regeneron and Alnylam are to research treatments for the chronic liver disease non-alcoholic steatohepatitis (NASH), under a new agreement. Alnylam specialises in treatments based around RNA ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA ...

"Always amazing to win an ICC event. I remember 2017 very closely, couldn't finish that time. Very pleased to have done it here," Hardik, who contributed significantly to India's title triumph on ...

After hours: March 13 at 7:55:58 PM EDT Loading Chart for REGN ...

Immune cells called natural killer cells can target and eliminate tumours. The gene expression and spatial distribution of the immune cells in the tumour microenvironment indicates whether liver ...